Literature DB >> 19528064

New coagulant agent (ankaferd blood stopper) for open hemorrhages in hemophilia with inhibitor.

Ahmet Faik Öner1, Murat Doğan, Avni Kaya, Ertan Sal, Mehmet Selçuk Bektaş, Osman Yesilmen, Harun Ayhan, Mehmet Acikgoz.   

Abstract

The treatment of hemophilia A patients with inhibitor could be very expensive. Ankaferd blood stopper (ABS) is a unique folkloric medicinal plant extract, which has historically been used in Turkish traditional medicine as a hemostatic agent. In this article, a 16-year-old boy was presented with uncontrolled bleeding, despite the treatment of factor VIII, rVIIa, factor VIII inhibitor bypass activity (FEIBA), cyclophosphamide, and prednisolone at circumcision site that resolved with ABS in minutes. Our patient with hemophilia A and inhibitor is the first clinical pediatric case.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19528064     DOI: 10.1177/1076029609337313

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  3 in total

1.  Management of Haemophilia in Developing Countries: Challenges and Options.

Authors:  Kanjaksha Ghosh; Kinjalka Ghosh
Journal:  Indian J Hematol Blood Transfus       Date:  2015-06-18       Impact factor: 0.900

2.  The Effectiveness of a New Hemostatic Agent (Ankaferd Blood Stopper) for the Control of Bleeding following Tooth Extraction in Hemophilia: A Controlled Clinical Trial.

Authors:  Hakkı Oğuz Kazancıoğlu; Onur Cakır; Gülsüm Ak; Bülent Zülfikar
Journal:  Turk J Haematol       Date:  2013-03-05       Impact factor: 1.831

3.  The Dual Diverse Dynamic Reversible Effects of Ankaferd Blood Stopper on EPCR and PAI-1 Inside Vascular Endothelial Cells With and Without LPS Challenge.

Authors:  Afife Karabıyık; Erkan Yılmaz; Sükrü Güleç; Ibrahim Haznedaroğlu; Nejat Akar
Journal:  Turk J Haematol       Date:  2012-12-05       Impact factor: 1.831

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.